BRIANNA AUSTIN: Open Payments
NPI 1316624455 · HARRISON, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$548 in 29 payments from 12 companies in 2025. Trend: 2023 $15 · 2024 $282 · 2025 $548
Food & beverage: $548
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 5 | $101 |
| Alkermes, Inc. | 5 | $84 |
| Otsuka America Pharmaceutical, Inc. | 3 | $62 |
| Vanda Pharmaceuticals Inc. | 2 | $58 |
| Supernus Pharmaceuticals, Inc. | 3 | $52 |
| ABBVIE INC. | 3 | $49 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| E.R. Squibb & Sons, L.L.C. | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
Products named: INGREZZA, ARISTADA, REXULTI, VRAYLAR, Auvelity, COBENFY, TRINTELLIX, HETLIOZ.
Industry payments across AR — which companies pay providers there.
